Loading...
In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF(165) neutralization
The stability, binding, and tissue penetration of variable new-antigen receptor (VNAR) single-domain antibodies have been tested as part of an investigation into their ability to serve as novel therapeutics. V13 is a VNAR that recognizes vascular endothelial growth factor 165 (VEGF(165)). In the pre...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6021326/ https://ncbi.nlm.nih.gov/pubmed/29963259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25549 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|